Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
Pharmaceutical company developing drugs for oncology and autoimmune diseases, focusing on TYK2/JAK1 inhibitors.
Founded in 2017 by Chris Liang, the inventor of sunitinib, and Incyte veteran Xiangdong Liu, HighlightLL Pharma is an innovative pharmaceutical company based in Hangzhou, Zhejiang Sheng, China. It specializes in developing breakthrough drugs for life-threatening oncology and autoimmune/inflammatory conditions, notably pioneering a selective TYK2/JAK1 inhibitor designed for better efficacy and reduced toxicity. The company has secured substantial funding, totaling RMB250 million ($38 million), including over RMB210 million ($30 million) from Series B and B+ rounds. These rounds were led by Hankang Capital, with participation from Kaitai Capital, eFung Capital, and Lakeside Capital. HighlightLL Pharma also advances virtual drug discovery models with in-house pipelines, including brain-penetrant inhibitors, aiming for improved efficacy and reduced toxicity. With approximately 18 employees, it targets global patients with unmet clinical needs.
HighlightLL Pharma has raised $43.7M across 2 funding rounds.
HighlightLL Pharma has raised $43.7M in total across 2 funding rounds.
HighlightLL Pharma has raised $43.7M in total across 2 funding rounds.
HighlightLL Pharma's investors include AstraZeneca, Efung Capital, Kaitai Capital.
HighlightLL Pharma has raised $43.7M across 2 funding rounds. Most recently, it raised $15.7M Series B in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 16, 2021 | $15.7M Series B | AstraZeneca | — | Announced |
| Jul 1, 2021 | $28M Series B | Efung Capital | Kaitai Capital | Announced |